EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY

被引：0
|
作者：
Chen, Bowen [1 ]
Zhang, Linzhi [2 ,3 ]
Cheng, Jiamin, Sr. [2 ]
Yan, Tao [2 ]
Lu, Yinying [1 ]
机构：
[1] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1045
引用
收藏
页码：637A / 638A
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
    Yang, Hui
    Yang, Tiequan
    Qiu, Guangpin
    Liu, Jie
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1435 - 1443
  • [32] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Renguo Guan
    Jie Mei
    Shaohua Li
    Wenping Lin
    Min Deng
    Wei Wei
    Rongping Guo
    Hepatology International, 2023, 17 : 765 - 769
  • [33] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Guan, Renguo
    Mei, Jie
    Li, Shaohua
    Lin, Wenping
    Deng, Min
    Wei, Wei
    Guo, Rongping
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 765 - 769
  • [34] Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study
    Xu, Bin
    Dong, Sanyuan
    Bai, Xue-Li
    Song, Tian-Qiang
    Zhang, Bo-Heng
    Zhou, Le-Du
    Chen, Yong-Jun
    Zeng, Zhi-Ming
    Wang, Kui
    Zhao, Hai-Tao
    Lu, Na
    Zhang, Wei
    Li, Xu-Bin
    Zheng, Su-Su
    Long, Guo
    Yang, Yu-Chen
    Huang, Hua-Sheng
    Huang, Lan-Qing
    Wang, Yun-Chao
    Liang, Fei
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Zhou, Jian
    Zeng, Meng-Su
    Fan, Jia
    Rao, Sheng-Xiang
    Sun, Hui-Chuan
    LIVER CANCER, 2023, 12 (03) : 262 - 276
  • [35] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
    O'Neil, Bert H.
    Wallmark, John M.
    Lorente, David
    Elez, Elena
    Raimbourg, Judith
    Gomez-Roca, Carlos
    Ejadi, Samuel
    Piha-Paul, Sarina A.
    Stein, Mark N.
    Razak, Albiruni R. Abdul
    Dotti, Katia
    Santoro, Armando
    Cohen, Roger B.
    Gould, Marlena
    Saraf, Sanatan
    Stein, Karen
    Han, Sae-Won
    PLOS ONE, 2017, 12 (12):
  • [36] MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy
    Sheng, Ruofan
    Zeng, Mengsu
    Jin, Kaipu
    Zhang, Yunfei
    Wu, Dong
    Sun, Huichuan
    ACADEMIC RADIOLOGY, 2022, 29 (06) : 819 - 829
  • [37] Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
    Xue-Feng Liu
    Xiao-Dong Zhu
    Long-Hai Feng
    Xiao-Long Li
    Bin Xu
    Kang-Shuai Li
    Nan Xiao
    Ming Lei
    Hui-Chuan Sun
    Zhao-You Tang
    Experimental Hematology & Oncology, 11
  • [38] Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
    Liu, Xue-Feng
    Zhu, Xiao-Dong
    Feng, Long-Hai
    Li, Xiao-Long
    Xu, Bin
    Li, Kang-Shuai
    Xiao, Nan
    Lei, Ming
    Sun, Hui-Chuan
    Tang, Zhao-You
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [39] The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study
    Yang, Zeran
    Chen, Guang
    Cui, Ye
    Xiao, Guowen
    Su, Tianhao
    Yu, Jianan
    Zhang, Zhiyuan
    Han, Yanjing
    Yang, Kailan
    Jin, Long
    CANCER BIOLOGY & THERAPY, 2019, 20 (03) : 321 - 327
  • [40] The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345